Insights

Professional

Practice

Industry

Region

Firm News 9 results

Firm News | 3 min read | 06.11.25

Crowell & Moring Attorneys and Practices Recognized in Managing IP’s 2025 IP Stars Guide

Chicago – June 11, 2025: Managing Intellectual Property has recognized 12 Crowell & Moring attorneys and four practices in its 2025 IP Stars guide. The guide, which is in its seventh edition, “brings together the world’s foremost law firm and corporate trademark experts, allowing the wider community to benefit from their insight, experience and perspectives.”

...

Firm News | 3 min read | 05.30.25

IAM Ranks Crowell & Moring in Patent 1000 2025

Intellectual Asset Management recognized Crowell & Moring in its IAM Patent 1000 – The World’s Leading Patent Practitioners guide, awarding the firm a gold band ranking as one of the top three firms handling patent litigation and transactions in Belgium, and a silver ranking for the firm’s Chicago office. The firm was also recommended nationally in the United States for trade secrets litigation. This marks the twelfth consecutive year that the firm has been ranked in the guide in Belgium.

Firm News | 2 min read | 04.23.25

Laura Lydigsen and Jason Stiehl Named to Crain’s Chicago Business 2025 Notable Litigators & Trial Attorneys List

Chicago – April 23, 2024: Laura Lydigsen, co-chair of Crowell & Moring’s Intellectual Property Department, and Jason Stiehl, managing partner of the firm’s Chicago office, have been named to Crain’s Chicago Business’ 2025 list of Notable Litigators & Trial Attorneys. The list features 92 attorneys shaping Chicago's legal landscape from high-stakes litigation to precedent-setting appellate rulings.

Client Alerts 14 results

Client Alert | 4 min read | 04.10.25

Hikma and Amici Curiae Ask Supreme Court to Revisit Induced Infringement by Generic “Skinny Labels”

In Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., C.A. No. 20-1630 (D. Del.), brand manufacturer Amarin brought an induced infringement claim against Hikma’s generic icosapent ethyl product, which lists Amarin’s Vascepa® as the reference listed drug. Vascepa was originally approved by the U.S. Food and Drug Administration (“FDA”) to treat severe hypertriglyceridemia, and later, Amarin obtained patents and approval for Vascepa as a treatment to reduce cardiovascular risk in certain patient populations. Hikma’s Abbreviated New Drug Application (“ANDA”) for generic icosapent ethyl included a Section viii statement that Hikma was not seeking approval for the patented cardiovascular indication along with a “skinny label” that included only the indication for severe hypertriglyceridemia.

...

Client Alert | 6 min read | 10.23.24

Unfinished Business in Congress on Drug Patents and Competition

Before leaving for an extended recess period ahead of the November general election, Congress left unfinished several proposals with ramifications for generic and biosimilar drug competition. This client alert summarizes some of that legislation and possible next steps in the “lame duck” period before the end of the year.

...

Client Alert | 4 min read | 04.18.24

Maryland and Colorado Say the Price Isn’t Right: State Drug Affordability Review Boards Seek Drug Upper Payment Limits

Following federal lawmakers’ initiative to lower prescription drug prices under the Inflation Reduction Act of 2022, several states have taken similar steps to limit certain drugs’ prices. Drug affordability for consumers is a top priority for federal and state lawmakers and regulators because it is a bipartisan issue that directly impacts consumers’ wallets. With negotiations between the federal government and drug manufacturers over 10 drugs’ prices for Medicare beneficiaries well underway under the Inflation Reduction Act, 11 states, including Maryland and Colorado, have created drug affordability review boards to more directly tackle rising prices for both brand and generic drugs.[1] And another 12 states have pending legislation to create these boards.[2]

...